Ultrasound surveillance for cholangiocarcinoma in an endemic area: A prove of survival benefits

Cholangiocarcinoma (CCA) is an aggressive malignancy with rapid progression and poor prognosis. Abdominal ultrasound surveillance may detect early‐stage malignancy and improve surgical outcome. However, little data exist on the benefits of abdominal ultrasound surveillance in populations at high risk for CCA development in an endemic area. This study compared survival outcomes of CCA patients recruited through abdominal ultrasound surveillance program and those presented to the hospital independent of surveillance.

[1]  Weijing Sun,et al.  Targeted therapy in biliary tract cancers-current limitations and potentials in the future. , 2017, Journal of gastrointestinal oncology.

[2]  M. Mino‐Kenudson,et al.  Cholangiocarcinoma: classification, diagnosis, staging, imaging features, and management , 2017, Abdominal Radiology.

[3]  W. Palmer,et al.  Update on the Diagnosis and Treatment of Cholangiocarcinoma , 2017, Current Gastroenterology Reports.

[4]  D. Ribero,et al.  Current Status on Cholangiocarcinoma and Gallbladder Cancer , 2016, Liver Cancer.

[5]  S. Siripongsakun,et al.  Ultrasound screening for cholangiocarcinoma could detect premalignant lesions and early-stage diseases with survival benefits: a population-based prospective study of 4,225 subjects in an endemic area , 2016, BMC Cancer.

[6]  Graciela Nogueras,et al.  Biostatistics in Public Health Using STATA , 2016 .

[7]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[8]  C. Pairojkul,et al.  Histological confirmation of periductal fibrosis from ultrasound diagnosis in cholangiocarcinoma patients , 2014, Journal of hepato-biliary-pancreatic sciences.

[9]  A. Loukas,et al.  The tumorigenic liver fluke Opisthorchis viverrini--multiple pathways to cancer. , 2012, Trends in parasitology.

[10]  H. Thomas,et al.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update , 2012, Gut.

[11]  T. Patel,et al.  Cholangiocarcinoma: new insights into disease pathogenesis and biology. , 2010, Infectious disease clinics of North America.

[12]  James R. Egner,et al.  AJCC Cancer Staging Manual , 2010 .

[13]  E. Gaudio,et al.  Cholangiocarcinoma: update and future perspectives. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[14]  D. Alvaro,et al.  New insights on cholangiocarcinoma. , 2010, World journal of gastrointestinal oncology.

[15]  Yasunori Sato,et al.  Multistep carcinogenesis of perihilar cholangiocarcinoma arising in the intrahepatic large bile ducts. , 2009, World journal of hepatology.

[16]  D. Alvaro.  Serum and bile biomarkers for cholangiocarcinoma , 2009, Current opinion in gastroenterology.

[17]  A. Ruzzenente,et al.  Intrahepatic Cholangiocarcinoma: Prognostic Factors After Surgical Resection , 2009, World Journal of Surgery.

[18]  C. Pairojkul,et al.  Cholangiocarcinoma: lessons from Thailand , 2008, Current opinion in gastroenterology.

[19]  S. Taylor-Robinson,et al.  Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. , 2008, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[20]  N. Malla,et al.  Association of parasitic infections and cancers. , 2005, Indian journal of medical microbiology.

[21]  H. El‐Serag,et al.  The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.

[22]  K. Marumo,et al.  Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer. , 2004, Japanese journal of clinical oncology.

[23]  T. Patel.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States , 2001, Hepatology.

[24]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[25]  James S Goydos,et al.  Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. , 1998, Annals of surgery.

[26]  A. Weaver,et al.  "Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. , 1995, Mayo Clinic proceedings.

[27]  P. Johnson,et al.  Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma , 1991, Cancer.